Evaluation of at risk generic entry in reverse payment matter

antitrust and competition

In a reverse payment matter, CRA was retained by the generic first filer. CRA’s expert opined on the business justifications for the generic manufacturer to enter into the patent settlement agreement and the economic rationale whether to launch at risk. The case ultimately settled mid-trial.

Meet our team

Additional Contributors